Midostaurin (PKC412)

Catalog No.S8064 Synonyms: CGP 41251

Molecular Weight(MW): 570.64

Midostaurin (pkc412) is a multi-targeted kinase inhibitor, including PKCα/β/γ, Syk, Flk-1, Akt, PKA, c-Kit, c-Fgr, c-Src, FLT3, PDFRβ and VEGFR1/2 with IC50 ranging from 80-500 nM.

Purity & Quality Control

Choose Selective PKC Inhibitors

Biological Activity

Description

Targets

PKCα ^[1] (Cell-free assay)	PKCγ ^[1] (Cell-free assay)	PKCβ1 ^[1] (Cell-free assay)	PKCβ2 ^[1] (Cell-free assay)	PPK ^[1] (Cell-free assay)	View More
22 nM	24 nM	30 nM	31 nM	38 nM	View More

In vitro

Midostaurin(pkc412) is a broad spectrum protein kinase inhibitor. Midostaurin(pkc412) interacts strongly with ATP binding sites of the conventional PKC-α, -β and -γ, PDGFRβ, VEGF-R2, VEGF-R1 and the cyclin-dependant kinase 1-cyclin B complex. Midostaurin(pkc412) inhibits the growth of various human and animal cell lines in vitro at similar submicromolar concentrations. Midostaurin(pkc412) also effectively inhibits the in vitro proliferation of glioblastoma and induced the accumulation of cells in G2/M and formation of giant nuclei with extensive fragmentation and apoptotic bodies. Midostaurin(pkc412) is able to reverse the p-glycoprotein-mediated multidrug resistance of tumor cells in vitro. ^[1]

Cell Data

Cell Lines	Assay Type	Incubation Time	Activity Description	PMID
human MV4-11 cells	M3PPVmN6fG:2b4jpZ4l1gSCjc4PhfS=>	NV\0OoxMPzJiaB?=	MXHDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDNWlQuOTFiY3XscJMh[W[2ZYKgO\|IhcHK\|IHL5JINmdGxidHn0[ZIu[my3ZTDhd5NigSxiSVO1NF0yOiCwTR?=	NVjrPYdQOTl4NUS0NFg>
RS4-11 cells	M17ubWZ2dmO2aX;uJIF{e2G7	NUnRdIlCOiCq	M2S5eWlvcGmkaYTpc44hd2ZiRlzUN{BKXERibYX0ZY51KGG3dH;wbI9{eGixconsZZRqd25iaX6gbJVu[W5iUmO0MVEyKGOnbHzzJIFnfGW{IEKgbJJ{KGK7IHXs[YN1em:laHXtbYx2dWmwZYPj[Y5k\SCjc4PhfUwhUUN3ME2xN{BvVQ>?	NXrkcpd5OTl4NUS0NFg>
CGTH-W-1 cell	NYDJNY9vT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		NHTqcItKdmirYnn0bY9vKG:oIHj1cYFvKEOJVFitW{0yKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:PDJwNkWg{txO	MWTTRW5ITVJ?
SW982 cell	MXnHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		NG\rbFdKdmirYnn0bY9vKG:oIHj1cYFvKFOZOUiyJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9OFUvPThizszN	NYOxc5VIW0GQR1XS
human EoL-1-cell cell	M4Gydmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		NUTaU4ZWUW6qaXLpeIlwdiCxZjDoeY1idiCHb1ytNU1k\WyuIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO\|YYmsJGlEPTB;NUKuNFghdk1?	NGXpeJpUSU6JRWK=
MOLM-13 cells	M4O0U2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7	MWC3NkBp	NYTWWmMzUW6qaXLpeIlwdiCxZjDGUHQ{KEmWRDDo[ZRmem:8eXfveZMhdXW2YX70JIlvKGi3bXHuJG1QVE1vMUOgZ4VtdHNiYYPz[ZN{\WRiYYOgZ4VtdCCpcn;3eIghcW6qaXLpeIlwdiCjZoTldkA4OiCqcoOgZpkhVVSVIHHzd4F6NCCJSUWwQVAvODV3IN88US=>	NWfXNFd{OjZyOEGwNlM>
KASUMI-1 cell	M3z0[Gdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		MVHJcohq[mm2aX;uJI9nKGi3bXHuJGtCW1WPST2xJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NE4xPjBzNjFOwG0>	NUf4NotTW0GQR1XS
NCI-H1755 cell	MUXHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		M3rGXGlvcGmkaYTpc44hd2ZiaIXtZY4hVkOLLVixO\|U2KGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:OC5yNkK3N{DPxE1?	NVPrTZExW0GQR1XS
human MES-SA cell	MXjHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		NYLnU5NxUW6qaXLpeIlwdiCxZjDoeY1idiCPRWOtV2Eh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0xNjB5NUS0JO69VQ>?	M3PFbHNCVkeHUh?=
human HCC1395 cell	MWnHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		NYTUUXdyUW6qaXLpeIlwdiCxZjDoeY1idiCKQ1OxN\|k2KGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:OC5yOESyPEDPxE1?	MnfaV2FPT0WU
human D-336MG cell	M{LkcWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		NG\Mc4xKdmirYnn0bY9vKG:oIHj1cYFvKERvM{O2UWch[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0xNjB6N{W0JO69VQ>?	NFO5cGZUSU6JRWK=
CHP-212 cell	MnizS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		NVnYUpI2UW6qaXLpeIlwdiCxZjDoeY1idiCFSGCtNlEzKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:OC5yOEe3N{DPxE1?	M3HGSnNCVkeHUh?=
human KM12 cell	MULHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		M2\2cmlvcGmkaYTpc44hd2ZiaIXtZY4hU01zMjDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyPUCuNFkzPzVizszN	M2qzO3NCVkeHUh?=
A204 cell	NUS3WmY3T3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		MnLlTY5pcWKrdHnvckBw\iCqdX3hckBCOjB2IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO\|YYmsJGlEPTB;MD6xNFA2OiEQvF2=	NXzad\|BJW0GQR1XS
CAL-51 cell	M3XGO2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7		Ml\ZTY5pcWKrdHnvckBw\iCqdX3hckBESUxvNUGgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2wMlExPzB7IN88US=>	M3nhOXNCVkeHUh?=
human A431 cell	M2fNc2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7		NF7RfpFKdmirYnn0bY9vKG:oIHj1cYFvKEF2M{GgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2wMlEyOjF4IN88US=>	NUfqVJE5W0GQR1XS
NCI-H650 cell	NFznUYxIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		MmnWTY5pcWKrdHnvckBw\iCqdX3hckBPS0lvSE[1NEBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVAvOTF5MEig{txO	NH\RWpFUSU6JRWK=
A427 cell	MlzGS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		MlXqTY5pcWKrdHnvckBw\iCqdX3hckBCPDJ5IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO\|YYmsJGlEPTB;MD6xNVkyQCEQvF2=	MUDTRW5ITVJ?
human 769-P cell	NHnFbJZIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		M3Xm[mlvcGmkaYTpc44hd2ZiaIXtZY4hPzZ7LWCgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2wMlEzODh{IN88US=>	M1;FTHNCVkeHUh?=
SW1710 cell	MkXIS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		M4fUbGlvcGmkaYTpc44hd2ZiaIXtZY4hW1dzN{GwJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NE4yOzNzNjFOwG0>	NXi4cHBKW0GQR1XS
human H4 cell	NYGx[oFoT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		MmS0TY5pcWKrdHnvckBw\iCqdX3hckBJPCClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR\|UxRTBwMUO5OlMh\|ryP	M3PHVnNCVkeHUh?=
HT-1080 cell	MnXlS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		NVnpNHg2UW6qaXLpeIlwdiCxZjDoeY1idiCKVD2xNFgxKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:OC5zNUm4NkDPxE1?	M{\oXnNCVkeHUh?=
human PANC-03-27 cell	NHHIUFZIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		NGX4SItKdmirYnn0bY9vKG:oIHj1cYFvKFCDTlOtNFMuOjdiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1yLkG2NFIh\|ryP	MlLGV2FPT0WU
A375 cells	MlqxR5l1d3SxeHnjbZR6KGG\|c3H5	M1[0SVczKGh?	MoH4WI95cWOrdImgZYdicW6\|dDDoeY1idiCDM{e1JINmdGy\|IHHmeIVzKDd{IHjyd{BjgSClZXzsJJRqfGW{LXLseYUh[XO\|YYmsJGlEPTB;MD6xPEDPxE1?	NGDrblYyQTZ3NESwPC=>
human HOP-62 cell	MoK2SpVv[3Srb36gZZN{[Xl?		NF[3fJRKdmirYnn0bY9vKG:oIHj1cYFvKEiRUD22NkBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVAvOThyN{Og{txO	M2TKdnNCVkeHUh?=
human U031 cell	MX;Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		M{PIZmlvcGmkaYTpc44hd2ZiaIXtZY4hXTB\|MTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyPUCuNVk3QThizszN	NFOwVXZUSU6JRWK=
mouse BAF3 cells	NIPlbWJRem:uaX\ldoF1cW:wIHHzd4F6		MVHBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IH3veZNmKEKDRkOgZ4VtdHNidILhcpNnd3KvZXSge4l1cCCcTl[xPVguTkeIUkGgZ49ve3S{dXP0MEBKSzVyPUCuNkDPxE1?	M1GxOlIyQTN4NUSy
human G-402 cell	Ml7VS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		M1vYRmlvcGmkaYTpc44hd2ZiaIXtZY4hTy12MEKgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2wMlIxOjV\|IN88US=>	NH7BZmJUSU6JRWK=
human G-361 cell	M{\DfGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		NUWyb\|lKUW6qaXLpeIlwdiCxZjDoeY1idiCJLUO2NUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVAvOjB6NUOg{txO	NWnzOpQ6W0GQR1XS
NCI-H810 cell	M17xWGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		NYnxRm55UW6qaXLpeIlwdiCxZjDoeY1idiCQQ1mtTFgyOCClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR\|UxRTBwMkGwNlch\|ryP	M4HBSnNCVkeHUh?=
NCI-H2030 cell	MVTHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		NIrzOZlKdmirYnn0bY9vKG:oIHj1cYFvKE6FST3INlA{OCClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR\|UxRTBwMkOwNFYh\|ryP	MVPTRW5ITVJ?
human HCT-116 cell	NUfab4dUT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		MkTKTY5pcWKrdHnvckBw\iCqdX3hckBJS1RvMUG2JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NE4zOzV4ODFOwG0>	NHjTeHhUSU6JRWK=
human SNU-423 cell	NG\CdW1Iem:5dHigbY5pcWKrdHnvckBie3OjeR?=		NVq5[I5QUW6qaXLpeIlwdiCxZjDoeY1idiCVTmWtOFI{KGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:OC5{M{[1O{DPxE1?	MYrTRW5ITVJ?
human SCC-4 cell	NHP4[3FIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		MmH1TY5pcWKrdHnvckBw\iCqdX3hckBUS0NvNDDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyPUCuNlM6PjdizszN	NV[zUoN2W0GQR1XS
human SW48 cell	M1;OWGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		Ml;GTY5pcWKrdHnvckBw\iCqdX3hckBUXzR6IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO\|YYmsJGlEPTB;MD6yOlY5KM7:TR?=	NFTkNJdUSU6JRWK=
human SF295 cell	MYXHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		M{KzWmlvcGmkaYTpc44hd2ZiaIXtZY4hW0Z{OUWgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2wMlI4OjV5IN88US=>	NYT2c\|FMW0GQR1XS
MDA-MB-231 cell	MU\Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		MXrJcohq[mm2aX;uJI9nKGi3bXHuJG1FSS2PQj2yN\|Eh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0xNjJ6MUCxJO69VQ>?	NW[0NnBNW0GQR1XS
A172 cell	MmXyS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		NXjwUVJOUW6qaXLpeIlwdiCxZjDoeY1idiCDMUeyJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NE4zQTF3IN88US=>	M3fQO3NCVkeHUh?=
human BCPAP cell	Mn;vS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		MYjJcohq[mm2aX;uJI9nKGi3bXHuJGJEWEGSIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO\|YYmsJGlEPTB;MD6yPVg4QSEQvF2=	MYLTRW5ITVJ?
human COLO-792 cell	M2XzTGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		MlWwTY5pcWKrdHnvckBw\iCqdX3hckBEV0yRLUe5NkBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVAvOjl7N{Kg{txO	NYDsTW1iW0GQR1XS
human DU-145 cell	MmGzS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		M{\OO2lvcGmkaYTpc44hd2ZiaIXtZY4hTFVvMUS1JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NE4{OTh6OTFOwG0>	NHr0T4FUSU6JRWK=
NCI-H2122 cell	M36xeGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		M13uSGlvcGmkaYTpc44hd2ZiaIXtZY4hVkOLLViyNVIzKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:OC5\|MkK4OUDPxE1?	M4L6cnNCVkeHUh?=
human SK-UT-1 cell	NEf2UmdIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		MUTJcohq[mm2aX;uJI9nKGi3bXHuJHNMNVWWLUGgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2wMlMzQTV{IN88US=>	M4fjVXNCVkeHUh?=
LXF-289 cell	NYLUdYJtT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		NX7EU21zUW6qaXLpeIlwdiCxZjDoeY1idiCOWF[tNlg6KGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:OC5\|Mkm2OUDPxE1?	NYHxRVhlW0GQR1XS
human NCI-H1792 cell	NF34V2dIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		M2rRUWlvcGmkaYTpc44hd2ZiaIXtZY4hVkOLLVixO\|kzKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:OC5\|M{C5OkDPxE1?	Mnq4V2FPT0WU
MCF7 cell	NWm5UoY1T3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		MUPJcohq[mm2aX;uJI9nKGi3bXHuJG1ETjdiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1yLkOzNlc1KM7:TR?=	MXjTRW5ITVJ?
HCT-15 cell	NIL3c2VIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		Ml3LTY5pcWKrdHnvckBw\iCqdX3hckBJS1RvMUWgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2wMlM{PDN{IN88US=>	MYHTRW5ITVJ?
human NCI-H358 cell	MYjHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		MWDJcohq[mm2aX;uJI9nKGi3bXHuJG5EUS2KM{W4JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NE4{OzV3MTFOwG0>	NXnENXBLW0GQR1XS
human HLE cell	M1Wwc2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7		NVjmRop7UW6qaXLpeIlwdiCxZjDoeY1idiCKTFWgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2wMlM{PzV{IN88US=>	NHHxTWRUSU6JRWK=
human SW1088 cell	NVXINZhxT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		NYXHclFmUW6qaXLpeIlwdiCxZjDoeY1idiCVV{GwPFgh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0xNjN\|N{m3JO69VQ>?	M1;odHNCVkeHUh?=
human K5 cell	MkTFS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		Mm\xTY5pcWKrdHnvckBw\iCqdX3hckBMPSClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR\|UxRTBwM{[xOFkh\|ryP	M2q5PXNCVkeHUh?=
human SR cell	Mm\LS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		M4PKSWlvcGmkaYTpc44hd2ZiaIXtZY4hW1JiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1yLkO2OVcyKM7:TR?=	M4fuVHNCVkeHUh?=
human Calu-3 cell	MXHHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		MonQTY5pcWKrdHnvckBw\iCqdX3hckBE[Wy3LUOgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2wMlM3QDJ3IN88US=>	Mmj0V2FPT0WU
human SK-MEL-30 cell	MWLHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		NX;rdWlqUW6qaXLpeIlwdiCxZjDoeY1idiCVSz3NSWwuOzBiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1yLkO5PVE{KM7:TR?=	MV;TRW5ITVJ?
human SW780 cell	NEjOOItIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		NH62[nFKdmirYnn0bY9vKG:oIHj1cYFvKFOZN{iwJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NE41OTF2MjFOwG0>	M{DVRnNCVkeHUh?=
NCI-H1563 cell	MnvoS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		NYj4cIh{UW6qaXLpeIlwdiCxZjDoeY1idiCQQ1mtTFE2PjNiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1yLkSxOFg1KM7:TR?=	MYDTRW5ITVJ?
human MKN45 cell	M{fWWmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		Mn\kTY5pcWKrdHnvckBw\iCqdX3hckBOU052NTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyPUCuOFE6OzFizszN	MXLTRW5ITVJ?
MDA-MB-157 cell	NF\IVWtIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		NFPNd4JKdmirYnn0bY9vKG:oIHj1cYFvKE2GQT3NRk0yPTdiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1yLkSyNFE2KM7:TR?=	NY[5NFJoW0GQR1XS
human NCI-H522 cell	M320dWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		NFXISFVKdmirYnn0bY9vKG:oIHj1cYFvKE6FST3IOVIzKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:OC52MkOg{txO	M{fvWnNCVkeHUh?=
human A2780 cell	MXPHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		M3;pdmlvcGmkaYTpc44hd2ZiaIXtZY4hSTJ5OECgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2wMlQ4PTB\|IN88US=>	MYjTRW5ITVJ?
human A498 cell	M4XsS2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7		M2TJS2lvcGmkaYTpc44hd2ZiaIXtZY4hSTR7ODDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyPUCuOFc3QTNizszN	M{PtXXNCVkeHUh?=
human BxPC-3 cell	MmrVS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		M1XSbmlvcGmkaYTpc44hd2ZiaIXtZY4hSniSQz2zJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NE41QTN4NjFOwG0>	NF7YXFFUSU6JRWK=
human A2058 cell	MWnHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		M33RTGlvcGmkaYTpc44hd2ZiaIXtZY4hSTJyNUigZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2wMlUzQDR2IN88US=>	NFLXSHdUSU6JRWK=
human PC-14 cell	NUH5RYQ5T3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		NUXQfJN2UW6qaXLpeIlwdiCxZjDoeY1idiCSQz2xOEBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVAvPTN6NUWg{txO	MUDTRW5ITVJ?
human KG-1 cell	NVvVfWF4T3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		NXPYWGV5UW6qaXLpeIlwdiCxZjDoeY1idiCNRz2xJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NE42PTRzOTFOwG0>	MU\TRW5ITVJ?
human A375 cell	MU\Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		MWHJcohq[mm2aX;uJI9nKGi3bXHuJGE{PzViY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1yLkW2NVA{KM7:TR?=	M2nyb3NCVkeHUh?=
human SW1783 cell	NVjHSmlGT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		MUXJcohq[mm2aX;uJI9nKGi3bXHuJHNYOTd6MzDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyPUCuO\|M{PyEQvF2=	NYPGTY1oW0GQR1XS
human MKN1 cell	NUOxNmdWT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		MUnJcohq[mm2aX;uJI9nKGi3bXHuJG1MVjFiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1yLki4OFEzKM7:TR?=	NUC2S2tXW0GQR1XS
NCI-H1650 cell	MWLHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		M3jsSGlvcGmkaYTpc44hd2ZiaIXtZY4hVkOLLVixOlUxKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:OC56OEmxOwOBiM7:TR?=	MkHZV2FPT0WU
human HT-1376 cell	NYKxWJROT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		M4XafmlvcGmkaYTpc44hd2ZiaIXtZY4hUFRvMUO3OkBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVAvQTJ7MUig{txO	MVLTRW5ITVJ?
SW872 cell	NYPwUm52T3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		M1\T[mlvcGmkaYTpc44hd2ZiaIXtZY4hW1d6N{KgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2wMlk1PDV7IN88US=>	NUP4cIlnW0GQR1XS
human RT-112 cell	NVXSe3l4T3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		MmXITY5pcWKrdHnvckBw\iCqdX3hckBTXC1zMUKgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2wMlk4PDh\|IN88US=>	M{T1fHNCVkeHUh?=
human HT-29 cell	NHj4SlNIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		NFTuOWJKdmirYnn0bY9vKG:oIHj1cYFvKEiWLUK5JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NE46Pzl7NjFOwG0>	NWPxVlNqW0GQR1XS
human U-266 cell	MlfvS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		MV3Jcohq[mm2aX;uJI9nKGi3bXHuJHUuOjZ4IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO\|YYmsJGlEPTB;MD65PFMxOiEQvF2=	NVfucW84W0GQR1XS
human HEL cell	NHvVfIJIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		NX;hUXNNUW6qaXLpeIlwdiCxZjDoeY1idiCKRVygZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2wMlk5PTF5IN88US=>	Mnz5V2FPT0WU
human KU812 cell	NWnRPZlST3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		M{T0[WlvcGmkaYTpc44hd2ZiaIXtZY4hU1V6MUKgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2xMlEyOTZ2IN88US=>	M4DkZXNCVkeHUh?=

... Click to View More Cell Line Experimental Data

In vivo

Midostaurin(pkc412) may suppress tumor growth by inhibiting tumor angiogenesis (via its effects on the VEGF receptor tyrosine kinases) in addition to directly inhibiting tumor cell proliferation (via its effects on PKCs). This anti-angiogenic action may contribute to the antimetastatic and broad antitumor activity displayed by midostaurin(pkc412), as well as the synergy with cytotoxic agents, including doxorubicin, cyclophosphamide, cisplatin and gemcitabine. When given orally, the maximally tolerated dose for midostaurin(pkc412) is >300 mg/kg. ^[1]

Protocol

Cell Research:^[2]	+ Expand Cell lines: A549, NCI-H520 Concentrations: ~1.0 μM Incubation Time: 24-72 h Method: Each well is added with 5 mM WST-1 and 0.2 mM 1-methoxy PMS and the absorbance at 450 nm is measured by a Microplate Reader. (Only for Reference)
Animal Research:^[1]	+ Expand Animal Models: Colo 205 colorectal tumors xenograft Formulation: sterile water Dosages: 50 mg/kg, 200 mg/kg, once daily Administration: p.o. (Only for Reference)

References

Solubility (25°C)

In vitro	DMSO	100 mg/mL (175.24 mM)
	Ethanol	20 mg/mL warmed (35.04 mM)
	Water	Insoluble
In vivo	Add solvents to the product individually and in order(Data is from Selleck tests instead of citations): 5% DMSO+45% PEG 300+ddH2O For best results, use promptly after mixing.	4mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information Download Midostaurin (PKC412) SDF

Molecular Weight	570.64
Formula	C₃₅H₃₀N₄O₄
CAS No.	120685-11-2
Storage	3 years -20°C powder
Storage	2 years -80°C in solvent
Synonyms	CGP 41251

Bio Calculators

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

Serial Dilutions
Concertration (start):
Dilution-folds:

Computed Result

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2018-10-19)

NCT Number	Recruitment	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT01429337	Recruiting	Hepatic Impairment	Novartis Pharmaceuticals\|Novartis	March 7 2011	Phase 1
NCT03280030	Recruiting	Acute Myeloid Leukemia	Novartis Pharmaceuticals\|Novartis	April 6 2018	Phase 2
NCT01883362	Completed	Acute Myeloid Leukemia	Novartis Pharmaceuticals\|Novartis	February 6 2014	Phase 2
NCT02634827	Active not recruiting	Acute Myeloid Leukemia With FLT3/ITD Mutation\|Acute Myeloid Leukemia With Gene Mutations\|FLT3 Tyrosine Kinase Domain Point Mutation\|Secondary Acute Myeloid Leukemia\|Untreated Adult Acute Myeloid Leukemia	Mayo Clinic\|National Cancer Institute (NCI)	December 30 2015	Phase 2
NCT00045942	Completed	Acute Myeloid Leukemia\|Myelodysplastic Syndromes	Novartis Pharmaceuticals\|Novartis	January 30 2002	Phase 1\|Phase 2
NCT03092674	Recruiting	Acute Myeloid Leukemia\|Adult Myelodysplastic Syndrome\|Myelodysplastic Syndrome With Excess Blasts-2\|Untreated Adult Acute Myeloid Leukemia	National Cancer Institute (NCI)	December 22 2017	Phase 2\|Phase 3

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

PKC Signaling Pathway Map

Related PKC Products0

SD-208 ^New

SD-208 is a selective TGF-βRI (ALK5) inhibitor with IC50 of 48 nM, >100-fold selectivity over TGF-βRII.
LDN-214117 ^New

LDN-214117 is a potent and selective BMP type I receptor kinase ALK2 inhibitor with IC50 of 24 nM.
Staurosporine

Staurosporine is a potent PKC inhibitor for PKCα, PKCγ and PKCη with IC50 of 2 nM, 5 nM and 4 nM, less potent to PKCδ (20 nM), PKCε (73 nM) and little active to PKCζ (1086 nM) in cell-free assays. Also shows inhibitory activities on other kinases, such as PKA, PKG, S6K, CaMKII, etc. Phase 3.
Sotrastaurin

Sotrastaurin is a potent and selective pan-PKC inhibitor, mostly for PKCθ with K_i of 0.22 nM in a cell-free assay; inactive to PKCζ. Phase 2.

Features:Unlike former PKC inhibitors, Sotrastaurin does not enhance apoptosis of murine T-cell blasts in a model of activation-induced cell death.
Go 6983

Go 6983 is a pan-PKC inhibitor against for PKCα, PKCβ, PKCγ and PKCδ with IC50 of 7 nM, 7 nM, 6 nM and 10 nM, respectively; less potent to PKCζ and inactive to PKCμ.
Enzastaurin (LY317615)

Enzastaurin (LY317615) is a potent PKCβ selective inhibitor with IC50 of 6 nM in cell-free assays, 6- to 20-fold selectivity against PKCα, PKCγ and PKCε. Phase 3.
Bisindolylmaleimide I (GF109203X)

Bisindolylmaleimide I (GF109203X) is a potent PKC inhibitor with IC50 of 20 nM, 17 nM, 16 nM, and 20 nM for PKCα, PKCβI, PKCβII, and PKCγ in cell-free assays, respectively, showing more than 3000-fold selectivity for PKC as compared to EGFR, PDGFR and insulin receptor.

Features:Greater selectivity than PKC inhibitor staurosporine. GF109203X is a chemical probe for studying PKC signal transduction pathways. Potential for use in a variety of cancers.
Go6976

Go6976 is a potent PKC inhibitor with IC50 of 7.9 nM, 2.3 nM, and 6.2 nM for PKC (Rat brain), PKCα, and PKCβ1, respectively. Also a potent inhibitor of JAK2 and Flt3.
Bisindolylmaleimide IX (Ro 31-8220 Mesylate)

Bisindolylmaleimide IX (Ro 31-8220 Mesylate) is a pan-PKC inhibitor with IC50 of 5 nM, 24 nM, 14 nM, 27 nM, and 24 nM for PKC-α, PKC-βI, PKC-βII, PKC-γ, and PKC-ε, respectively, and also shows potent inhibition against MAPKAP-K1b, MSK1, GSK3β and S6K1.

Choose Your Country or Region

By Signaling Pathways

By product type

Midostaurin (PKC412)

Purity & Quality Control

Choose Selective PKC Inhibitors

Biological Activity

Protocol

References

Solubility (25°C)

Chemical Information Download Midostaurin (PKC412) SDF

Bio Calculators

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Dilution Calculator

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

The Serial Dilution Calculator Equation

Serial Dilutions

Computed Result

Molecular Weight Calculator

Total Molecular Weight: g/mol

Instructions to calculate molar mass (molecular weight) of a chemical compound:

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2018-10-19)

Tech Support

PKC Signaling Pathway Map

Related PKC Products0

Choose Your Country or Region

By Signaling Pathways

By product type

Midostaurin (PKC412)

Purity & Quality Control

Choose Selective PKC Inhibitors

Biological Activity

Protocol

References

Solubility (25°C)

Chemical Information Download Midostaurin (PKC412) SDF

Bio Calculators

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Dilution Calculator

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

The Serial Dilution Calculator Equation

Serial Dilutions

Computed Result

Molecular Weight Calculator

Total Molecular Weight: g/mol

Instructions to calculate molar mass (molecular weight) of a chemical compound:

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2018-10-19)

Tech Support

PKC Signaling Pathway Map

Related PKC Products0

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)